RxDoctor Payments Data

Saurin Patel, MD

Interventional Cardiology · Patchogue, NYNPI 1245648203

Payments from drug & device makers

$9,148in general payments, 2019–2025

Across 132 payments — averaging $69.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$6K
  • Abbott$484
  • Novartis$412
  • Penumbra, Inc.$398
  • Lilly USA, LLC$274
  • Boston Scientific$230
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$1,63125%
  • Food & beverage$4,38168%
  • Education$4367%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,148 in reported general payments places this provider in the 45th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$410,654
Medicare patients
323
Services billed
2,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$66,404
XareltoRivaroxaban20$22,459
WegovySemaglutide14$18,198
EntrestoSacubitril/Valsartan16$17,694
BrilintaTicagrelor17$8,618
Valsartan48$701
Metoprolol Succinate66$675
Amlodipine Besylate122$573
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$498
Losartan Potassium76$484
Rosuvastatin Calcium62$473
Atorvastatin Calcium55$472
Hydrochlorothiazide70$335
Lisinopril54$249
Ramipril20$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$188$66,40467 claims
Johnson & JohnsonXarelto$185$22,45920 claims
Novo NordiskWegovy$174$18,19814 claims
NovartisEntresto$412$17,69416 claims
AstraZenecaBrilinta$43$8,61817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Patchogue

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →